The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease

European Journal of Neuroscience

Volumn 26, Issue 2, 2007, Pages 417-423

  Abuirmeileh, Amjad ^a   Lever, Rebecca ^a   Kingsbury, Ann E ^d   Lees, Andrew J ^d   Locke, Ian C ^b   Knight, Richard A ^c   Chowdrey, Hardial S ^b   Biggs, Christopher S ^b   Whitton, Peter S ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

6 hydroxydopamine; Dopamine; Lipopolysaccharide; Rat; Tyrosine hydroxylase; Urocortin

Indexed keywords

APOMORPHINE; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; LEVODOPA; LIPOPOLYSACCHARIDE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UROCORTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CIRCLING BEHAVIOR; COMPARATIVE STUDY; CORPUS STRIATUM; DISEASE COURSE; IN VIVO STUDY; INJECTION; KNOWLEDGE; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

ANIMALS; APOMORPHINE; BLOTTING, WESTERN; CORTICOTROPIN-RELEASING HORMONE; DATA INTERPRETATION, STATISTICAL; DOPAMINE; LIPOPOLYSACCHARIDES; MALE; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 34447624725     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2007.05653.x     Document Type: Article

References (43)

1. Abercrombie, E.D., Bonatz, A.E. Zigmond, M.J. (1990) Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res., 525, 36 44.
2. Bagosi, Z., Jasazberenyi, M., Bujdoso, Z. Telegdy, Z. (2006) The effects of corticoptropin-releasing factor and the urocortins on striatal dopamine release induced by electrical stimulation - an in vitro superfusion study. Neurochem. Res., 31, 209 213.
3. Biggs, C.S., Fowler, L.J., Pearce, B.R. Whitton, P.S. (1992) Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine and their metabolites in the rat brain: An in vivo microdialysis study. JNeurochem., 59, 1702 1708.
4. Biggs, C.S., Abuirmeileh, A., Locke, I.C., Knight, R.A., Chowdrey, H.S. Whitton, P.S. (2006) Urocortin attenuates key indicators of nigrostriatal pathway destruction in a rat hemiparkinsonian model. Proc. Brit. Pharm. Soc. http://www.pA2online.org/abstracts/vol31issue4abst162.
5. Block, M.L. Hong, J.S. (2005) Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog. Neurobiol., 76, 77 98.
6. Block, M.L., Zecca, L. Hong, J.-S. (2007) Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Neurosci., 8, 57 69.
7. Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R. Verna, J.-M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol., 65, 135 172.
8. Borta, A. Hoglinger, G.U. (2007) Dopamine and adult neurogenesis. J. Neurochem., 100, 587 595.
9. Brar, B.K., Jonassen, A.K., Stephanou, A., Santilli, A., Railson, J., Knight, R.A., Yellon, D.M. Latchman, D.S. (2000) Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. JBiol. Chem., 275, 8508 8514.
10. Brar, B.K., Railson, J., Stephanou, A., Knight, R.A. Latchman, D.S. (2002) Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. JEndocrinol., 172, 283 293.
11. Choi, J.S., Pham, T.T., Jang, Y.J., Bui, B.C., Lee, B.H., Boo, K.M., Cha, C.I. Lee, K.H. (2006) Corticotropin-releasing factor (CRF) and urocortin promote the survival of cultured cerebellar GABAergic neurons through the type 1 CRF receptor. JKorean Med. Sci., 21, 518 526.
12. Clark, D. White, F.J. (1987) D1 dopamine receptor the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse, 1, 347 388.
13. Cutillas, B., Espejo, M., Gil, J., Ferrer, I. Ambrosio, S. (1999) Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration. Neuroreport, 10, 2605 2608.
14. Facci, L., Stevens, D.A., Pangallo, M., Franceschini, D., Skaper, S.D. Strijbos, P.J.L.M. (2003) Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology, 45, 623 636.
15. Gandhi, S. Wood, N.W. (2005) Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet., 14, 2749 2755.
16. Gao, H.M., Liu, B., Zhang, W. Hong, J.S. (2003a) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J., 17, 1957 1971.
17. Gao, H.M., Liu, B., Zhang, W. Hong, J.S. (2003b) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci., 24, 395 401.
18. Gonzalez-Rey, E., Fernandez-Martin, A., Chomy, A. Delgado, M. (2006) Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut, 55, 824 832.
19. He, Y., Lee, T. Leong, S.K. (2000) 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res., 858, 163 166.
20. Herrera, A.J., Castano, A., Venero, J.L., Cano, J. Machado, A. (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis., 7, 429 447.
21. Hurtig, H.I. (1997) Problems with current pharmacological treatment of Parkinson's disease. Exp. Neurol., 144, 10 16.
22. Intekhad-Alam, N.Y., Chowdrey, H.S., Knight, R.A. Locke, I.C. (2004) A CRF family peptide protects a human chondrocyte cell line against apoptosis. Osteoarthr. Cartilage, 12 (Suppl. B 107.
23. Lewis, K., Li, C., Perrin, M.H., Blount, A., Kunitake, K.S., Donaldson, C., Vaughan, J., Reyes, T.M., Gulyas, J., Fischer, W., Bilezikjian, L., Rivier, L., Sawachenko, P.E. Vale, W.W. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl Acad. Sci., 98, 7570 7575.
24. Meissner, W.T., Hill, M.P., Tison, F., Gross, C.E. Bezard, E. (2004) Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trend Pharmacol. Sci., 25, 249 253.
25. Mochizuki, H., Goto, K., Mori, Y. Mizuno, Y. (1996) Histochemical detection of apoptosis in Parkinson's disease. JNeurol. Sci., 137, 120 123.
26. Nanmoku, T., Takekoshi, K., Fukuda, T., Isobe, K., Shibuya, S. Kawakami, Y. (2005) Urocortin stimulates tyrosine hydroxylase activity via the cAMP/protein kinase a pathway in rat Pheochromocytoma PC12 cells. Neurosci. Lett., 382, 124 127.
27. Naoi, M., Takahashi, T. Nagatsu, T. (1988) Simple assay procedure for tyrosine hydroxylase activity by high-performance liquid chromatography employing coulometric detection with minimal sample preparation. JChromatogr., 427, 229 238.
28. Ochu, E.E., Rothwell, N.J. Waters, C.M. (1998) Caspases mediate 6-hydroxydopamine induced apoptosis but not necrosis in PC12 cells. JNeurochem., 70, 2637 2640.
29. Pederson, W.A., Wan, R., Zhang, P. Mattson, M.P. (2002) Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type 1. JNeurosci., 22, 404 412.
30. Reul, J.M. Holsboer, F. (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol., 2, 23 33.
31. Reyes, T.M., Lewis, K., Perrin, M.H., Kunitake, K.S., Vaughan, J., Arias, C.A., Hogenesch, J.B., Gulyas, J., Rivier, J., Vale, W.W. Sawchenko, P.E. (2001) Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl Acad. Sci., 98, 2843 2848.
32. Sauvage, M. Steckler, T. (2001) Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei - potential implication for arousal and attention. Neuroscience, 104, 643 652.
33. Scarabelli, T.M., Pasini, E., Stephanou, A., Comini, L., Curello, S., Raddino, R., Ferrari, R., Knight, R.A. Latchman, D.S. (2002) Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. JAm. Coll. Cardiol., 40, 155 161.
34. Schapira, A.H. (2001) Causes of neuronal death in Parkinson's disease. Adv. Neurol., 86, 155 162.
35. Swinny, J.D., Metzger, F., Ijkema-Passen, J., Gounko, N.V., Gramsbergen, A. Van Der Want, J.J. (2004) Corticotropin-releasing factor and urocortin differentially modulate rat Purkinje cell dendritic outgrowth and differentiation in vitro. Eur. J. Neurosci, 19, 1749 1758.
36. Takahashi, K., Totsune, K., Sone, M., Murakami, O., Satoh, F., Arihara, Z., Sasano, H., Lino, K. Mouri, T. (1998) Regional distribution of urocortin-like immunoreactivity and expression of urocortin mRNA in the human brain. Peptides, 19, 643 647.
37. Tao, J., Zhang, Y., Soong, T.W. Li, S. (2006) Expression of urocortin 2 and its inhibitory effects on intracellular Ca2+ via L-type voltage gated calcium channels in rat pheochromocytoma (PC12) cells. Neuropsychopharmacology, 31, 2600 2609.
38. Tatton, N.A., Maclean-Fraser, A., Tatton, W.G., Perl, D.P. Olanow, C.W. (1998) A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol., 44, S142 S148.
39. Ungerstedt, U. (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl., 367, 8993.
40. Vasconcelos, L.A., Donaldson, C., Sita, L.V., Casatti, C.A., Lotfi, C.F., Wang, L., Cardinouch, M.Z., Frigo, L., Elias, C.F., Lovejoy, D.A. Bittencourt, J.C. (2003) Urocortin in the central nervous system of a primate (Cebus Apella): sequencing, immunohistochemical, and hybridization histochemical characterization. JComp. Neurol., 463, 157 175.
41. Vaux, D.L. Korsmeyer, S.J. (1999) Cell death in development. Cell, 96, 245 254.
42. Whitton, P.S. (2007) Neuroinflammation as a causative factor in Parkinson's disease. Br. J. Pharmacol., 150, 963 976.
43. Yamamoto, H. (1998) Urocortin-like immunoreactivity in the substantia nigra, ventral tegmental area and Edinger-Westphal nucleus of rat. Neurosci. Lett., 243, 21 24.